110P - Safety and effectiveness of adebrelimab as first-line treatment in extensive-stage small-cell lung cancer: A prospective, real-world study

Background

The CAPSTONE-1 study established adebrelimab combined with carboplatin and etoposide as the first-line standard of care for patients with extensive-stage small-cell lung cancer (ES-SCLC) in China; however, the clinical outcomes of adebrelimab in routine practice remain largely unknown, particularly among patients with brain metastases. Here, we present the first evaluation of the safety and effectiveness of adebrelimab for the first-line treatment of ES-SCLC in a real-world setting.

Methods

In this prospective, multicenter, observational study in China, patients with ES-SCLC who were scheduled to receive adebrelimab-based first-line treatment at the discretion of the investigator were included. The primary outcome was safety profiles according to CTCAE version 5.0. Secondary outcomes included objective response rate (ORR), disease control rate (DCR), duration of response, progression-free survival (PFS), and overall survival (OS).

Results

Between March 9, 2023 and May 7, 2024, 188 patients were included (median age 64 years [range 41-85], 158 [84%] males, 65 [34.6%] current smokers, 42 [22.3%] with brain metastases, 52 [27.7%] with liver metastases, and 79 [42.0%] with pleural effusion). As of August 21, 2024, the median follow-up duration was 5.6 months (IQR 4.1-7.8). Among the 188 patients, the real-world ORR was 65.4% (95% CI 58.2-72.2, and the real-world DCR was 85.1% (95% CI 79.2-89.9). Median PFS was 6.9 months (95% CI 5.8-7.2), with a 6-month PFS rate of 56.9% (95% CI 48.0-64.9). Median PFS was 5.4 months (95% CI 4.8-7.5) in patients with brain metastases and 7.0 months (95% CI 5.9-7.6) in those without brain metastases, without statistical difference (P=0.110). OS data are not mature yet. Treatment-emergent adverse events (TEAEs) of any grade were reported in 166 (88.3%) patients, and grade 3 or worse TEAEs occurred in 60 (31.9%) patients.

Conclusions

This real-world study enrolled a broader and more diverse SCLC patient population compared to the CAPSTONE-1 trial. Despite this, adebrelimab-based regimen showed favorable effectiveness and a manageable safety profile in the first-line setting for ES-SCLC, offering additional pivotal data to the CAPSTONE-1 trial.

Legal entity responsible for the study

The authors.

Funding

Jiangsu Hengrui Pharmaceuticals Co., Ltd.

Disclosure

All authors have declared no conflicts of interest.